Inositol Hexakisphosphate and Inositol Enhance the Inhibition of Colorectal Cancer Growth and Liver Metastasis by Capecitabine in a Mouse Model

To investigate the effects of inositol hexaphosphate (IP6) and inositol (INS) with capecitabine treatment on colorectal cancer (CRC) growth and liver metastasis in mice, we established an orthotopic xenograft mouse model. The study designated five experimental groups: a control group, a model group, a capecitabine (60 mg/kg) treatment group, an IP6 + INS (80 mg/kg: 80 mg/kg) treatment group, and a capecitabine + IP6 + INS (60 mg/kg: 80 mg/kg: 80 mg/kg) treatment group. Compared with the model group, the tumor parameters of the other three treatment groups were significantly reduced. The combination of IP6 and INS with capecitabine is more effective in improving survival rate, reducing tumor weight, and inhibiting liver metastasis. Compared with the model group, the expression of E-cadherin in each treatment group was elevated, while the expression of N-cadherin and vimentin was suppressed. This phenomenon was more obvious in the combination group. The combination more significantly reduced the expression levels of TNF-alpha, IL-6, and IL-8 in the serum of CRC mice compared with other intervention groups. Our data indicate that IP6 and INS enhanced the effect of capecitabine on CRC growth in mice by modulating the expression of inflammatory factors, intercellular adhesion molecules, and vimentin.

Automated summary

The study demonstrates that the combination of IP6 and INS with capecitabine significantly improves survival rate, reduces tumor weight, and inhibits liver metastasis in a mouse model of colorectal cancer. Furthermore, this combined treatment effectively modulates the expression of inflammatory factors, intercellular adhesion molecules, and vimentin, enhancing the therapeutic effect on CRC growth.